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ABSTRACT
Obinutuzumab (GA101) is a novel, type II,
glycoengineered, humanized anti-CD20
monoclonal antibody that has been developed
to address the need for new therapeutics with
improved efficacy in patients with lymphocytic
leukemia and lymphoma of B-cell origin.
Obinutuzumab has a distinct mode of action
relative to type I anti-CD20 antibodies, such as
rituximab, working primarily by inducing direct
cell death and antibody-dependent
cell-mediated cytotoxicity. Obinutuzumab is
under investigation in a wide-ranging program
of clinical trials in patients with B-cell
malignancies. Efficacy as monotherapy has
been reported in patients with relapsed/
refractory indolent and aggressive
non-Hodgkin lymphoma (NHL) and in chronic
lymphocytic leukemia (CLL) of B-cell origin.
Improved outcomes have also been noted when
obinutuzumab is added to chemotherapy in
patients with B-cell NHL, and superiority over
rituximab has been reported with combination
therapy in patients with CLL. Ongoing research
is focusing on developing options for
chemotherapy-free treatment and on new
combinations of obinutuzumab with novel
targeted agents.
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INTRODUCTION
Lymphocytic leukemia and lymphomas are
malignant neoplasms that disrupt normal
lymphocyte development and function.
Lymphocytic leukemia originates in bone
marrow and is characterized by high numbers
of abnormal lymphocytes in the blood [1].
Chronic lymphocytic leukemia (CLL) is a slowly
progressing disease that affects B lymphocytes
(B-cells), mainly in older adults, and is the most
common form of leukemia in the Western world,
with an annual incidence rate of 4.2 per 100,000
[2]. Lymphomas, on the other hand, encompass
a group of hematologic malignancies that arise
mainly from mature T lymphocytes (T cells) or
B-cells in secondary lymphoid tissue, particularly
the lymph nodes [3, 4]. They are subdivided
based on the presence of Reed-Sternberg (or
Hodgkin) cells into Hodgkin lymphoma (HL)
and non-Hodgkin lymphoma (NHL) [5], of
which NHL is by far the most common
(accounting for around 90% of cases) [6].
There are many types of NHL, differing in
terms of microscopic appearance, growth
patterns, clinical impact, and treatment [3, 4].
However, NHL can be broadly divided into two
major groups, B-cell and T-cell NHLs, of which
the B-cell type accounts for approximately 85%
of all cases [5]. Indolent NHL (iNHL) is a
slow-growing form of B-cell NHL that includes
follicular lymphoma (FL) and marginal zone
lymphoma, whereas more aggressive and
faster-growing presentations of NHL include
diffuse large B-cell lymphoma (DLBCL),
Burkitt’s lymphoma, and mantle cell
lymphoma (MCL) [6].
FL is the most common type of iNHL, with
an annual incidence that has risen from 2 to 3
per 100,000 in the 1950s to 5 to 7 per 100,000
more recently in Western Europe [7]. Median
age at diagnosis is in the 6th decade of life, but
up to 25% of patients with FL are aged 40 years
or younger [8]. Approximately 55–70% of
patients have bone marrow involvement at
presentation, which is indicative of advanced
disease [9–11]. Among aggressive subtypes of
NHL, DLBCL is the most prevalent [12], having
a crude annual incidence in Europe of 3.8 per
100,000 and accounting for between 30% and
58% of all cases of NHL [13]. Incidence of
DLBCL increases with age, and risk factors
include a family history of lymphoma,
autoimmune disease, human
immunodeficiency virus or hepatitis C virus
infection, high body mass in young adulthood,
and some types of occupational hazard
exposure [13].
Management of NHL and CLL depends on
stage, tumor burden, and other patient factors.
For example, recent guidelines state that
patients with early (stage I–II) iNHL should be
offered radiotherapy [8, 14, 15], which can
result in 10-year overall survival (OS) rates of
up to 80% [14, 15]. However, most patients with
iNHL are incurable [15], and successive relapses
and increasing resistance to treatment
characterize the individual course of the
disease. Until the late 1990s (i.e., the period
preceding the introduction of antibody
therapy), these patients were usually treated
with increasingly intensive combination
chemotherapy regimens to reduce tumor
burden and palliate symptoms. Response rates
to conventional chemotherapy generally
exceeded 50% [12], and maximal tumor
reduction could be achieved with high-dose
chemotherapy and autologous stem cell
support, but there were no apparent
improvements in failure-free survival [16].
Treatment of symptomatic CLL and the more
aggressive forms of NHL have also traditionally
relied heavily on intensive combination
chemotherapy.
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The therapeutic landscape for all forms of
B-cell NHL changed markedly in the late 1990s
with the approval of a CD20-directed
monoclonal antibody (mAb), rituximab, after
demonstration of significant activity as a single
agent in patients with iNHL [17, 18]. The
antigen CD20 is a membrane protein found
on the surface of all mature B-cells that typically
has a constitutive and constant expression and
therefore provides an excellent therapeutic
target [19]. Moreover, it is found in 95% of
B-cell malignancies [20]. Rituximab acts by
engaging Fc receptors on immune effector





addition to exerting direct antiproliferative
and pro-apoptotic effects [12, 21].
The development of rituximab initiated the
introduction of targeted immunotherapy for
the treatment of indolent and aggressive forms
of B-cell NHL and CLL and improved the
general prognosis for patients with these
diseases [9]. For instance, using a series of
patients (with previously untreated stage I–II
FL) from Stanford University, Tan et al.
described four eras of FL treatment from 1960
to 2003: pre-anthracycline (1960–1975, 180
patients), anthracycline (1976–1986, 426
patients), aggressive chemotherapy/purine
analogs (1987–1996; 471 patients), and
rituximab (1997–2003, 257 patients) [22].
Median OS improved from 11 years in eras 1
and 2 to 18.4 years in era 3; at the time of
reporting in 2013, median OS for era 4 had not
been reached [22]. The development of
rituximab in combination with chemotherapy
represented a major step forward, significantly
improving survival outcomes in not only
patients with FL [23] but also in other
CD20-positive B-cell malignancies, including
DLBCL [24, 25] and CLL [26]. These advances
led to the adoption of rituximab as standard of
care in patients with CLL, FL, and DLBCL who
require systemic therapy [2, 8, 13, 14].
Despite the major therapeutic advances
brought about by rituximab [15, 27], relapse
and development of resistance to treatment are
eventually seen in the majority of B-cell NHL
patients [12, 15, 28]. The disease course is
characterized thereafter by an ongoing
decrease in the quality and duration of
response with each subsequent course of
therapy [15]. Mechanisms of resistance that
have been suggested include increased mAb
metabolism, reduced tumor penetration,
reduced mAb binding (via FccRIII
polymorphisms), resistance to mAb effector
mechanisms, complement depletion,
abnormal lipid raft composition of some
malignant B-cells, downregulation of
pro-apoptotic proteins, and impairments in
immune effector cell recruitment or function
[29, 30].
CD20 ‘shaving’ is another potential
resistance mechanism to type I anti-CD20
mAbs, whereby mAb-CD20 complexes are
rapidly removed from the surface of B-cells via
monocytes/macrophages through a mechanism
known as trogocytosis [31–33]. This resistance
mechanism can lead to fewer cell-surface CD20
antigens (with a consequent reduction in
anti-CD20 mAb binding) and a decrease in
Fc-mediated effector functions as well as a
reduced mAb half-life. Additionally, there is
evidence to indicate that FccRIIb-mediated
internalization and degradation of the
complex formed between the mAb and CD20
from the surface of some B-cell malignancies
may cause resistance to type I anti-CD20 mAbs,
such as rituximab [34–36], although this process
of CD20 downregulation appears to be slower
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than trogocytosis [32]. This mechanism of
mAb-CD20 internalization limits the
engagement of natural effectors, reduces mAb
half-life, and increases mAb turnover [37].
mAb-CD20 internalization correlates strongly
with cis expression of the inhibitory Fc receptor
FccRIIb on target B-cells and has been shown to
predict less durable responses to rituximab
therapy in patients with MCL [37].
Management of relapse and resistance in
rituximab-treated patients presents a significant
challenge [6], and there is a need for treatments
with improved activity across B-cell NHL
subtypes and CLL. Better understanding of
antibody biology and modes of action,
together with increased ability to design
highly efficient therapeutics, has led to the
development of novel mAbs with improved
activity. As a review article, the following
paper does not contain any new studies with
human or animal subjects performed by any of
the authors.
OBINUTUZUMAB, A NOVEL
HUMANIZED TYPE II MAB
Obinutuzumab (GA101) is a novel, type II,
glycoengineered, humanized anti-CD20 mAb
that has been developed to address the need
for novel therapeutics with higher activity than
rituximab. The post-translational
glycoengineering process used in the
development of this agent [resulting in the
absence of a fucose sugar residue from
immunoglobulin G (IgG) oligosaccharides in
the Fc region of the mAb molecule] was
developed to increase activity by enhancing
binding affinity to the FccRIII receptor on
immune effector cells (Fig. 1) [38, 39].
Additionally, obinutuzumab has a modified
Fig. 1 Structure and binding behavior of obinutuzumab.
Glycoengineered structure and type II binding properties
of obinutuzumab. a Glycoengineering by defucosylation of
immunoglobulin G oligosaccharides in the Fc region of
obinutuzumab. In Chinese hamster ovary producer
cells, N-acetylglucosamine (NAG) is assembled into
oligosaccharides, which sterically prevents the addition of
fucose to the carbohydrate attached to asparagine (Asn)
297. b Hypothetical model of CD20 binding properties of
type I and II antibodies. In contrast to inter-tetrameric
CD20 binding of type I antibodies, intra-tetrameric
binding of type II antibodies to CD20 does not lead to
FccRIIb-mediated internalization of CD20 in lipid rafts
(reproduced from Goede et al. [38] with permission;
copyright  2015 Karger Publishers, Basel, Switzerland)
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elbow-hinge amino acid sequence compared to
type I agents, which together with the unique
epitope recognized by obinutuzumab results in
spatial alterations of the CD20-mAb complex
on B-cells [39, 40]; this is believed to be the
molecular basis for the type II biology of
obinutuzumab [40] as both type II character
and cell death induction (as described below)
can be switched on and off by mutating this
elbow-hinge region [39].
The type II mechanism of action of
obinutuzumab together with glycoengineering
acts to enhance direct cell death and ADCC/
ADCP, while decreasing CDC (Fig. 2) [41], and
differentiates the drug from classical type I
anti-CD20 mAbs, such as rituximab and
ofatumumab [39, 40, 42–44]. Rituximab, by
comparison, works primarily via CDC (by
clustering CD20 within lipid rafts) and by
ADCC/ADCP, with direct cell death
contributing much less to the overall
antitumor activity [45]. Ofatumumab also acts
primarily via CDC after binding both loop
domains of CD20 at a different epitope
compared to rituximab [46].
Increased Direct Cell Death Induction
Obinutuzumab has been shown to be faster
than and superior to both rituximab and
ofatumumab in inducing direct cell death in
malignant B-cells. This was demonstrated by
phosphatidylserine exposure and propidium
iodide staining [with analysis by
Fig. 2 Putative mechanisms of action of obinutuzumab.
Please refer to the text for further information and
supporting references. ADCC antibody-dependent cell-
mediated cytotoxicity, ADCP antibody-dependent cellular
phagocytosis, CDC complement-dependent cytotoxicity
(adapted from Goede et al. [41] with permission)
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fluorescence-activated cell sorting (FACS) and
time-lapse microscopy] in a panel of
CD20-expressing tumor cell lines [39, 43].
While some researchers have questioned the
validity of using FACS to assess mAb-induced
direct cell death (because of potential
mechanical interference with mAb-mediated
homotypic adhesion) [47], multiple studies,
using a variety of methods (including FACS),
have confirmed that, overall, obinutuzumab
induces greater direct cell death than type I
mAbs [48–53] and occurs without disruption of
homotypic aggregates [43, 54].
The mechanisms that may underlie the
ability of type II anti-CD20 mAbs to directly
evoke programmed cell death (PCD) are still
poorly understood, but have been investigated
in several studies [39, 48, 55]. Honeychurch
et al. demonstrated actin-dependent,
lysosome-mediated induction of PCD by type
II mAbs, such as obinutuzumab or
tositumomab, which was directly correlated
with the production of reactive oxygen species
(ROS) [48]. In contrast, type I mAbs, such as
rituximab, induced only minimal levels of ROS
and PCD. Generation of ROS mediated by
nicotinamide adenine dinucleotide phosphate
oxidase, independently of mitochondria, was
unaffected by B-cell lymphoma 2 (BCL-2)
overexpression and took place downstream of
mAb-induced actin cytoskeletal reorganization
and lysosome membrane permeabilization. The
results thus indicated a newly characterized cell
death pathway that is independent of the
classical hallmarks of apoptosis and has the
potential to bypass mechanisms of apoptotic
resistance, thereby eliminating malignant cells
that are refractory to conventional chemo- or
immunotherapy. A similar mechanism of cell
death has also been described for other
antibodies targeting B-cell surface antigens,
such as HLA-DR or CD37 [56, 57]. In a
separate study, Cheadle and colleagues found
that PCD induced by type II agents such as
obinutuzumab is a form of immunogenic cell
death that is characterized by the release of
damage-associated pattern molecules, including
heat shock protein 90 and adenosine
triphosphate. It is believed that this
mechanism of PCD could enhance the
immune response by inducing dendritic cell
mutation and subsequent T-cell proliferation
[49].
In contrast to these data, which are largely
based on NHL cell lines, ex vivo studies utilizing
CLL primary samples suggest that direct cell
death induction is not the major mechanism of
obinutuzumab-mediated B-cell depletion in CLL
[50, 55, 58–61]. This observation may be a
consequence of the lower proliferative state of
non-stimulated CLL cells, as compared to NHL
cell lines. Thus, in CLL, immune
effector-mediated mechanisms (as described
below) may play a more important role than
direct cell death induction in mediating the
antiproliferative effects of obinutuzumab. In line
with this assumption, a study has demonstrated
that CD40 stimulation can sensitize CLL cells to
lysosomal cell death induction by
obinutuzumab, providing evidence that drug
sensitivity in CLL cells can be modulated by
microenvironmental stimuli [55].
Complement-Dependent Cytotoxicity
Antibody-mediated CDC is initiated by fixing of
C1q (the initiating component of the classical
complement pathway) to the Fc portion of
target-bound antibodies. This triggers a
cascade that in turn leads to the formation of
C3 and C5 convertase and ultimately to the
membrane attack complex (MAC). The MAC
then causes cell lysis by disrupting the plasma
membrane of the target cell [62].
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The ability of CD20 antibodies to mediate
CDC appears to be determined by the effect of
mAb binding and cross-linking on the
redistribution of the target antigen into lipid
rafts on the surface of the target cell. The
density and positioning of the
antigen-antibody complexes influence C1q
binding and, in turn, the complement cascade
[62]. Complement recruitment as such is a key
characteristic distinction between type I CD20
mAbs, such as rituximab and ofatumumab,
which mediate strong CDC, and type II CDC
antibodies like obinutuzumab, which only
mediate weak CDC activity in cellular assays
[39, 42, 43]. CDC is therefore not thought to
contribute meaningfully to the overall activity
of obinutuzumab [38, 62]. Interestingly, the
limited capacity of obinutuzumab to fix
complement via its Fc portion may further
enhance its capability to bind to FccRIII and
mediate ADCC [63].
ADCC/ADCP
Glycoengineering as well as subsequent
enhancement of affinity for FccRIIIa (an
activating Fc receptor expressed primarily on
NK cells) was confirmed as the predominant
determinant of the superior ADCC activity of
obinutuzumab over type I anti-CD20 mAbs in a
series of experiments using NHL cell lines and
human PBMCs expressing the V158/V158 or
F158/F158 FccRIIIa receptor [43]. While
obinutuzumab was superior to rituximab and
ofatumumab in terms of potency and overall
cell killing, the ADCC activity of a
non-glycoengineered version of obinutuzumab
was similar to that of rituximab and
ofatumumab, confirming the additional
benefit conferred by glycoengineering [43].
Notably, the induction of ADCC was found to
be particularly more potent with obinutuzumab
than rituximab in the presence of nonspecific
human IgG at physiological concentrations, as
found in human blood [39].
In an assessment of ADCP, Herter et al. used
FACS analysis to show that obinutuzumab,
rituximab, and ofatumumab have comparable
overall phagocytic activity in NHL cell lines and
primary human monocyte-derived
macrophages (MDMs) [44]. Rafiq et al. have
demonstrated the phagocytic activity of
obinutuzumab against membrane-dyed CLL
cells undergoing flow cytometry, although
ofatumumab and rituximab produced greater
phagocytosis than obinutuzumab in these
experiments [50]. In a recent report, intravital
imaging revealed improved Kupffer
cell-mediated phagocytosis of B-cells as an
important in vivo mode of action of
glycoengineered anti-CD20 mAbs, such as
obinutuzumab, which underlies their
improved activity compared with
non-Fc-engineered antibodies [64].
ADCC is carried out mainly by NK cells, which
carry inhibitory killer cell immunoglobulin-like
receptors (KIRs) that interact with exposed
epitopes on the class I human leukocyte
antigen (HLA). Experiments using peripheral
blood mononuclear cells (PBMCs) from healthy
donors, primary CLL cells from patients, and a
variety of cell lines have shown that, because of
its Fc modification, obinutuzumab can
compensate for inhibitory KIR/HLA
interactions [65]. This results in the recruitment
of additional NK cells for ADCC, and target cell
depletion is not negatively impacted by KIR/HLA
interactions [65]. Genotyping of patients
participating in the CLL11 study (comparing
chlorambucil, rituximab-chlorambucil, and
obinutuzumab-chlorambucil in previously
untreated patients with CLL) has shown that
the prognosis for patients with a low number of
KIR/HLA interactions is better than that for
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patients with a higher number of such
interactions [66]. Taken together, these results
indicate that ADCC is a key mode of action for
obinutuzumab and is influenced by the number
of the inhibitory interactions.
Unlike type I anti-CD20 mAbs, type II agents
are found to undergo reduced CD20
internalization (Fig. 1) [67]. Indeed, increased
stability of surface-accessible CD20 was noted
with obinutuzumab relative to both rituximab
and ofatumumab using FACS in a human
DLBCL cell line and in blood from patients
with CLL [43]. Ultimately, this may further
enhance the immune effector cell-mediated
mechanisms of type II anti-CD20 mAbs,
independently of, but in conjunction with,
glycoengineering. Furthermore, type II
anti-CD20 mAbs may be less susceptible to the
development of resistance mechanisms
affecting effector-cell-mediated cytotoxicity.
The impact of trogocytosis on reducing the
efficacy of type II mAbs through shaving of
CD20 molecules from the cell surface requires
further investigation.
Superior and/or Faster Whole Blood B-cell
Depletion
Measurement of overall B-cell depletion in
whole blood allows all mechanisms of action
of therapeutic antibodies to be assessed in a
single assay. Potent B-cell depleting activity in
peripheral blood and lymphoid tissue superior
to that of rituximab has been reported with
obinutuzumab in non-human primate models
[39]. In addition, Mo¨ssner et al. showed
obinutuzumab to be significantly (10–25
times) more potent and 1.5–2.5 times more
effective (p\0.001) than rituximab in depleting
B-cells in whole blood from healthy human
donors [39]. These results were then confirmed
using primary malignant B-cells from a patient
with CLL [39]. Superior B-CLL cell depletion in
whole blood with obinutuzumab was
demonstrated independently by several other
research groups [50, 58, 60, 61], whereas
Bologna et al. showed that obinutuzumab
treatment depleted B-cells in whole blood
from CLL patients to a similar extent to
rituximab, but at a much faster rate [59].
These findings may reflect the different
experimental methods that were used but
overall demonstrate the enhanced
B-cell-depleting activity of obinutuzumab.
Recently, Ysebaert et al. described the effects
of rituximab and obinutuzumab on B-cell
depletion in 96 CLL patient samples with
different prognostic factors [68]. Median
proportions of B-cell depletion after
whole-blood assay were 22% with rituximab
and 63% with obinutuzumab (p\0.001),
independent of their prognostic factors [68].
Fig. 3 Percentage tumor growth inhibition (TGI) in combination studies of mouse Z138 MCL xenografts
[69]. *Statistically signiﬁcant (p\0.001; Tukey-Kramer test) vs. single-agent treatments.**Statistically signiﬁcant vs.
G monotherapy and RIT ? FLU. ***Statistically signiﬁcant vs. RIT monotherapy. TGI was calculated from tumor
volume (TV) [(length 9 width2)/2], calculated from staging until study termination, as follows:
TGI (%) = 100 Median ½TV treatedð ÞdayzTV treatedð Þdayx Median ½TV respective controlð Þ
dayz
TV respective controlð Þ
dayx
  100:
Each treatment group was compared with its respective vehicle control. TVday z represented TV for an individual
animal at a deﬁned study day (day z), and TVday x represented TV of an individual animal at the staging day (day x).
Animals in control groups received 0.9% sodium chloride vehicle; randomization to treatments took place 9–27 days
after tumor cell injection. Animals were killed at various time points from day 30 to day 66. BEN bendamustine, CHL
chlorambucil, FLU ﬂudarabine, G obinutuzumab (GA101), MCL mantle cell lymphoma, RIT rituximab, TGI tumor
growth inhibition
c
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Superior Antitumor Efficacy In Vivo
Finally, obinutuzumab has shown superiority
over rituximab in vivo in various human
lymphoma xenograft models [39].
Dose-dependent efficacy in the range of
1–30 mg/kg was noted in a staged aggressive
SU-DHL4 DLBCL model, with complete tumor
regression in all animals and lasting tumor
eradication in 90% at the highest dose of 30 mg/
kg. Incontrast, tumor regressionwas not shown at
any equivalent dose of rituximab [39] or with
ofatumumab [43]. In this model, second-line
obinutuzumab treatment was also effective in
inhibiting the progression of tumors that had
progressed under first-line treatment with
rituximab and that were no longer responsive to
rituximab [39] or ofatumumab [43]. Superior
efficacy of obinutuzumab over rituximab or
ofatumumab has also been shown in an
aggressive disseminated MCL model [39, 43].
Herting et al. described the antitumor activity of
obinutuzumab and rituximab alone and in
combination with bendamustine, fludarabine,
chlorambucil, doxorubicin, and
cyclophosphamide/vincristine in subcutaneous
murine xenograft models using Z138 MCL and
WSU-DLCL2 DLBCL tumors [69]. As
obinutuzumab had high single-agent activity in
these models, suboptimal doses were used in order
to observe combination effects. Superior tumor
growth inhibition was achieved with
obinutuzumab plus bendamustine over rituximab
plus bendamustine, and statistically significant
effects versus the respective single treatments
were also observed (Fig. 3). In addition,
obinutuzumab showed significantly greater
activity than rituximab when combined with
fludarabine, chlorambucil, or cyclophosphamide/
vincristine. Obinutuzumab monotherapy was as
effective as, or more effective than, rituximab plus
chemotherapy in vivo [69].
CLINICAL TRIALS
OF OBINUTUZUMAB IN B-CELL
NHL
Obinutuzumab is now under evaluation in an
extensive clinical trial program in patients with
B-cell malignancies.
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Obinutuzumab Monotherapy
Obinutuzumab given as monotherapy has been
investigated in the GAUGUIN study
(NCT00517530), a multicenter phase Ib/II
clinical trial in patients with B-cell
malignancies [70–73]. The primary objective of
the phase Ib part of the study was to investigate
the safety and tolerability of escalating
intravenous doses of obinutuzumab in patients
with CD20-positive lymphoid malignancies,
including NHL and CLL. This was followed by
a phase II part to study efficacy and safety.
Patients were adults aged 18 years or older with
an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2.
The first two reports from GAUGUIN
(Table 1) communicated phase I [70] and II
[71] results from patients with relapsed/
refractory iNHL, most of whom had FL. In the
phase I part, 21 patients (median of five prior
therapies, 20/21 with prior rituximab) received
escalating doses of obinutuzumab monotherapy
over eight 21-day cycles. The majority of
adverse events (AEs) were infusion-related
reactions (IRRs), nearly all of which were of
grade 1–2 in severity (Table 1).
IRRs with obinutuzumab, like those seen
with rituximab, have been attributed to
cytokine release. In previous studies of
rituximab, patients with IRRs were found to
release greater amounts of interleukin (IL)-8,
IL-6, and tumor necrosis factor-alpha than
those without IRRs [76–78]. Patients with a
baseline absolute lymphocyte count of
C50 9 109/l appear to have a particularly high
risk of developing IRRs [76–78]. The incidence
and severity of IRRs in patients treated with
obinutuzumab is reportedly greater than with
rituximab and has been linked to immediate
and marked release of IL-6 and IL-8 that is
limited to the first infusion and is accompanied
by rapid destruction of circulating B-cells and
disappearance of circulating NK cells from the
peripheral blood [79].
In GAUGUIN, 18 grade 3–4 AEs occurred in 7
patients; all treatment-related grade 4 events
were neutropenias, while most grade 3 AEs were
hematologic events and IRRs. Notably, there
were no dose-limiting toxicities (DLTs). Two of
nine rituximab-refractory patients showed a
tumor response, and the best overall response
rate (ORR) was 43%, with five complete
responses (CRs) and four partial responses
indicating the promising activity of
obinutuzumab.
Phase II data from relapsed/refractory iNHL
patients (n = 40; Table 1) showed promising
efficacy and acceptable tolerability, particularly
in the higher dose group (1600/800 mg) over a
median observation time of 33.7 months [71].
Of the phase II patients, 90% had stage III or IV
disease and had received a median of two prior
rituximab treatments (range 0–5); 45% and 55%
were refractory to their last treatment or to
rituximab, respectively. End-of-treatment ORRs
in rituximab-refractory patients were 8% in the
400/400 mg group and 50% in the 1600/800 mg
group. The two CRs were seen in the higher
dosage group.
The phase II GAUGUIN study for patients
with aggressive forms of B-cell NHL showed
similar tolerability and promising efficacy
(Table 1) [72]. These patients (25 with DLBCL
and 15 with MCL) had received a median of
three prior treatments (range 1–17), and 25
(63%) were rituximab-refractory. Of the 25
rituximab-refractory patients, 4 (16%) had
objective responses to induction treatment
and one responded during follow-up. Four of
the five responses were achieved at the
1600/800 mg dose. The best ORR in all
patients with aggressive B-cell NHL was 30%.
Median response duration (all responders) was
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9.8 months; there was no relevant difference in
progression-free survival (PFS) between dosage
groups after a median of 14.2 months (range
0.3–36.1 months) of observation. Based on both
these results and on pharmacokinetic modeling,
which showed that obinutuzumab 1000 mg per
cycle with additional 1000 mg doses on days 8
and 15 of cycle 1 can achieve exposures similar
to the 1600/800 mg regimen used in GAUGUIN
[80], a simplified flat-dose 1000 mg schedule
was adopted for subsequent phase II and III
investigation [81]. It has been hypothesized
that differences in CD20 binding, activation of
biological pathways, and underlying
mechanisms of action compared with type I
anti-CD20 mAbs permit the use of flat dosing
for obinutuzumab rather than conventional
body surface area-based dosing [80]. The
1000-mg flat-dose schedule for obinutuzumab,
which has been implemented as the standard
dose in clinical trials, rapidly achieves CD20
target saturation in all patients tested, with
serum concentrations maintained at this
therapeutic level throughout the treatment
course [80].
Among 13 phase I patients with relapsed/
refractory CLL in the separately reported
GAUGUIN CLL study, there was a median
response duration of 10.5 months (range
8.5–37 months) in eight partial responders (for a
best ORR of 62%; Table 1) [73]. Among 20 patients
with CLL who were recruited to phase II, the best
ORR was substantially lower (6/20; 30%). This
has been linked to a higher baseline tumor
burden and consequent lower treatment
exposure than in phase I [73]. Median
response duration was 8.9 months (range
0.8–26.1 months). Tolerability was acceptable in
other groups of patients, with IRRs being the most
common AEs (Table 1). Most notably, all CLL
patients treated in the GAUGUIN study
experienced a rapid and sustained elimination of
B-cells in the peripheral blood, which was
independent of the dose applied. These findings
provided the rationale for investigating
obinutuzumab in the phase III CLL11 trial. Data
from CLL11 and other dedicated studies in
patients with CLL are presented later in this
review.
Further data in larger numbers of patients
with relapsed iNHL were obtained from the
multicenter GAUSS study (NCT00576758) [74].
The initial phase I component of this trial
evaluated obinutuzumab doses of 200–2000 mg
given once weekly for 4 weeks (induction)
followed by maintenance therapy every
3 months for 2 years in 22 patients with
relapsed B-cell NHL (including 10 with FL) or
CLL [82]. The best ORR was 32%, with a response
observed in 15% of rituximab-refractory patients.
The maximum tolerated dose was not reached. A
flat dose of 1000 mg was selected for the phase II
part of GAUSS based on the phase I data and other
clinical experience. As summarized in Table 1,
175 patients with relapsed iNHL were enrolled to
phase II, of whom 149 had FL. The ORR at the end
of induction was higher with obinutuzumab
than with rituximab, as shown by investigator
assessments at the end of the induction period
(45% vs. 33%; p = 0.08) and by a blinded
independent review panel (45% vs. 27%;
p = 0.01) (Table 1). There was no significant
difference between treatments for the secondary
endpoint of PFS, but the study was not powered
to detect differences. AEs were balanced between
the two groups, but there were more IRRs and
coughs in the obinutuzumab group (Table 1)
[74].
An additional phase I study in 12 Japanese
patients, of whom 8 had FL, also showed no
DLTs [75]. B-cell depletion was seen in all
patients and persisted for the duration of
treatment. No disease progression was
observed during the treatment period.
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Moreover, the majority of AEs were of grade 1 or
2 in severity; as in other studies, IRRs
predominated (Table 1).
COMBINATION THERAPY
Phase I and II
Following the promising activity of
obinutuzumab in phase I and II single-agent
studies, a number of studies have been carried
out in the combination therapy setting. Thephase
Ib GAUDI study (NCT00825149) examined the
safety and antitumor activity of two doses of
obinutuzumab (G) (400/400 mg or 1600/800 mg)
combined with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP; G-CHOP), or
with fludarabine and cyclophosphamide (FC;
G-FC), as induction therapy in 56 patients with
relapsed/refractory FL (Table 2) [83]. These
patients had received up to six prior treatments.
Patients were allocated to either CHOP or FC by
their physicians on the basis of clinical need and
the physician’s judgment; allocation to the two
obinutuzumab dose regimens was randomized. As
seen in the previously described phase I and II
monotherapy studies, IRRs were the most
common AEs and were predominantly of mild
severity (Table 2). Two patients from the G-FC
400/400 mg arm and three from the G-FC
1600/800 mg arm discontinued treatment
because of AEs; one other patient in the latter
group discontinued because of insufficient
response. All rituximab-refractory patients
responded to treatment, and the high ORRs
noted (Table 2) supported future phase III
investigation [83].
As G-CHOP was seen to have a safety profile
similar to R-CHOP (rituximab combined with
CHOP), the design of the GAUDI study was
amended to compare the safety of
obinutuzumab plus CHOP or bendamustine in
81 treatment-naı¨ve patients with FL (Table 2)
[84]. After 2 years’ maintenance in initial
responders who went on to receive
obinutuzumab 1000 mg as monotherapy, high
CR rates were seen in both treatment arms and
opportunistic infections were infrequent [84].
G-CHOP was also investigated in the
first-line setting in 80 patients with advanced
DLBCL in the GATHER study (NCT01414855)
(Table 2) [85]. The ORR and CR rates as
determined by investigators were 83% and
55%, respectively (Table 2). IRRs, most of
which were grade 1–2 in intensity, were
typically observed during the first cycle.
Phase III
The phase III GADOLIN study (NCT01059630)
(Table 2) compared bendamustine monotherapy
(120 mg/m2 on day 1 and 2, for up to six 28-day
cycles) with obinutuzumab (1000 mg on day 1,
8, and 15 of cycle 1 and on day 1 of cycles 2–6 in
28-day cycles) plus bendamustine (90 mg/m2 on
day 1 and 2, for up to six 28-day cycles)
induction and obinutuzumab maintenance
(1000 mg every 2 months for 2 years or until
progression in patients achieving stable disease
or better with induction) in 396 patients with
rituximab-refractory iNHL who had received a
median of two prior treatments [86]. At a
preplanned interim analysis for efficacy,
enrollment was stopped and the trial was
analyzed in full, as the primary endpoint had
been met. Median observation time was
20.3 months for bendamustine alone and
21.9 months for obinutuzumab plus
bendamustine. Recruitment had been ongoing
between data cutoff and interim analysis, and a
significant number of patients were still
undergoing treatment. PFS was significantly
longer with combination therapy (median not
reached) than with bendamustine alone
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(median 14.9 months) as assessed by an IRF
[primary endpoint; hazard ratio (HR) 0.55; 95%
confidence interval (CI) 0.40–0.74; p = 0.0001].
Subgroup analyses and secondary endpoints
(including PFS by investigator and OS) were
consistent and supportive of the primary
endpoint. There were no significant differences
in IRF-assessed ORR or CR rate at the end of
induction. Whether this was due to the
differences between groups in bendamustine
dosage or to the different modes of action of
obinutuzumab and bendamustine was
uncertain (Table 2). The prognostic relevance
of minimal residual disease (MRD) status in 93
biomarker-evaluable patients with FL in
GADOLIN was also investigated [88]. MRD
analysis measures the small number of
malignant cells that remain after treatment.
MRD status was associated with clinical CR rate
and improved PFS, and significantly more
patients were MRD-negative after induction
with obinutuzumab plus bendamustine than
after bendamustine alone (82% vs. 43%;
p\0.0001). Median OS was not reached in
either arm at the time of reporting, but there
were more deaths due to disease progression
with bendamustine alone than with
obinutuzumab plus bendamustine [86].
Overall, grade C3 AEs were more common in
the obinutuzumab plus bendamustine group,
but grade C3 thrombocytopenia and anemia
were more frequent in the bendamustine-only
group (Table 2).
Emerging data from GADOLIN also suggest
improvements in health-related quality of life [89].
The time taken to a C6-point worsening from
baseline on the Functional Assessment of Cancer
Treatment-Lymphoma Trial Outcome Index
(FACT-Lym TOI) was 8.0 months in the
combination therapy arm and 4.6 months with
bendamustine alone. A higher proportion of
patients reported meaningful improvements on
the lymphoma subscale, lymphoma TOI, and total
score with obinutuzumab plus bendamustine than
with bendamustine alone [89].
Ongoing phase III combination therapy
studies with obinutuzumab include GALLIUM
(first-line advanced iNHL; NCT01332968) and
GOYA (first-line DLBCL; NCT01287741).
GALLIUM aims to assess the efficacy and
safety of obinutuzumab plus chemotherapy
versus rituximab plus chemotherapy followed
by maintenance immunotherapy. After
induction, responders will progress to
maintenance therapy with their randomized
antibody treatment alone, given every
2 months until disease progression or for a
maximum of 2 years. In May 2016, at a
prespecified interim analysis, the GALLIUM
Independent Data Monitoring Committee
recommended analysis of the study data as the
primary endpoint of investigator-reported PFS
had been met [90]. This is the second
head-to-head comparative trial against
rituximab that has shown a positive result for
obinutuzumab, the first being the CLL11 study
(described below). In the phase III GOYA trial,
previously untreated patients with DLBCL were
randomized to obinutuzumab 1000 mg every
21 days (with two additional doses on day 8 and
day 15 of cycle 1) or rituximab 375 mg/m2 every
21 days for eight cycles in addition to 6–8 cycles
of CHOP chemotherapy. Recruitment of 1418
patients was completed in 2014. After the final
analysis in July 2016, Roche issued a press
release to say that the study’s primary
endpoint of improvement in
investigator-assessed PFS had not been met.
Detailed results are expected to be announced
at ASH 2016.
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CLINICAL TRIALS
OF OBINUTUZUMAB IN CLL
Phase I and II
A number of studies have investigated the use of
obinutuzumab in patients with CLL. The GAGE
study (NCT01414205), a randomized, phase II
study in 80 symptomatic, untreated CLL
patients, demonstrated significant antitumor
activity with both 1000 mg and 2000 mg
dosages of obinutuzumab. End of induction
response was superior with the higher dosage
(Table 3) [91]. The results suggested a possible
dose-response relationship, but this requires
further investigation and longer follow-up.
Obinutuzumab has also shown manageable
toxicity and promising activity in combination
with either bendamustine or FC in the phase Ib
GALTON study (NCT01300247) in 41 patients
with previously untreated CLL [92].
Phase III
In the phase III CLL11 study (Table 3), 781
patients with previously untreated CLL and a
score higher than 6 on the Cumulative Illness
Rating Scale or an estimated creatinine clearance
of 30–69 ml/min were randomized to
chlorambucil alone, obinutuzumab plus
chlorambucil, or rituximab plus chlorambucil
for six 28-day cycles [93]. The main study
followed a safety run-in designed to ensure that
chlorambucil-containing chemoimmunotherapy
regimens were safe in recruitedolder patients with
comorbidities [94]. IRRs and neutropenia were
identified as potential risks during the run-in, but
none of the specified stopping criteria were met,
and the main study was opened for
randomization in April 2010.
Both combinations increased PFS
significantly over chlorambucil monotherapy;
obinutuzumab plus chlorambucil, but not
rituximab plus chlorambucil, prolonged OS
significantly (Table 3) [95]. Obinutuzumab plus
chlorambucil also conferred longer PFS (Table 3)
[93, 95] and a higher CR rate (21% vs. 7%) [93]
than rituximab plus chlorambucil, and it was
associated with significantly and substantially
increased time to next treatment (Table 3) [95].
AEs were reported at higher frequencies with
obinutuzumab plus chlorambucil than with
either of the other two treatments, but
toxicities were manageable and the risk of
infection was not increased over rituximab
plus chlorambucil or chlorambucil alone.
Among patients for whom MRD data were
available, the proportion who were
MRD-negative in bone marrow and peripheral
blood at the end of treatment was markedly
higher with obinutuzumab plus chlorambucil
than with rituximab plus chlorambucil
treatment (bone marrow, 18% vs. 3%;
peripheral blood, 36% vs. 3%) [96]. MRD
in peripheral blood at the end of treatment
was an independent prognostic factor for
both PFS (HR 5.29; 95% CI 3.48–8.04;
p\0.001) and OS (HR 3.04; 95% CI 1.53–6.03;
p = 0.002).
The GREEN study (NCT01905943) is an
ongoing, open-label, multicenter, phase IIIb
study in patients with previously untreated or
relapsed/refractory CLL receiving obinutuzumab
alone or in combination with chemotherapy
(bendamustine, FC, or chlorambucil). One of the
objectives of this study is to investigate the
potential of alternative obinutuzumab
administration protocols for reducing IRRs.
Emerging results suggest that the safety profile
of obinutuzumab plus bendamustine is
manageable if the appropriate measures are
taken (e.g., monitoring at-risk patients for
tumor lysis syndrome after the first infusion)
[97, 98].
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DOSE RATIONALE
In all phase III trials, obinutuzumab was, or is
being, administered at the aforementioned
rationally optimized 1000-mg flat-dose
schedule [80], compared with the standard,
approved 375 mg/m2 dose of rituximab in
iNHL/DLBCL or 500 mg/m2 in CLL. A
comparison of equal doses of the two mAbs
was not feasible in the phase III trials because of
the requirement for a third treatment arm and
the associated need to recruit many additional
patients. However, while there is controversy
over whether the approved dose of rituximab is
optimal, or which patients may benefit from a
higher dose [99], there is no clinical evidence
proving that increasing the dose of rituximab
leads to better long-term outcomes for patients
[100, 101]. Furthermore, differences between
the obinutuzumab and rituximab arms in the
CLL11 trial in terms of the kinetics of peripheral
B-cell depletion [102] and achievement of MRD
negativity [96] imply that the distinct biology of
the two mAbs has a greater influence on the
clinical results than the different dose
schedules, and as such, increasing the dose of
rituximab would be unlikely to result in
comparable outcomes to obinutuzumab.
SHORTER DURATION OF INFUSION
Reducing the duration of infusion for
intravenous drugs has potential advantages in
terms of patient and physician burden. Long
infusion times and frequent infusion rate
changes result in lengthy observation times,
increased nursing and administration staff
workloads, and inconvenience to patients [103].
A notable early example of research to
balance the benefits of shorter duration of
infusion (SDI) against the potentially increased
risk of hypersensitivity reactions was the effort
made in the 1990s to reduce paclitaxel infusion
times from 24 to 3 h [104]. Since then, SDI with
rituximab has been investigated in 351 patients
with rheumatoid arthritis in the RATE-RA study
(NCT01382940): there was no increase in the
rate or severity of IRRs when infusion times
were reduced from the standard 4.25 to 2 h
[103]. SDI with rituximab was subsequently
assessed in a phase III study in 425 patients
with DLBCL or FL [105]. Reduction of the
infusion time from a median of 240 min to a
fixed time of 90 min was found to be feasible in
patients who tolerated an initial infusion at the
longer standard rate. These observations led to
an increase in the recommended infusion rate
for rituximab to a maximum of 400 mg/h [106]
and to the investigation of SDIs in patients
receiving obinutuzumab. In the studies in
which SDI was investigated, patients received
obinutuzumab at the regular infusion rate for
the first cycle to establish safety (i.e., no IRRs of
grade C3) and activity (lymphocyte count
B5000/ll), after which SDI could be started
from cycle 2.
GATHER
The safety of SDI of obinutuzumab after cycle 1
was evaluated in the GATHER study (first-line
advanced DLBCL) (Table 2) [85]. After
treatment at the regular infusion rate was
deemed safe, based on 20 patients who
received the standard-rate infusion with
G-CHOP therapy, patients who met the SDI
inclusion criteria (who had not experienced a
serious and/or grade C3 IRR and had a
lymphocyte count B5000/ll) were treated at
the SDI rate. Initially three patients in the
cohort received obinutuzumab over 120 min;
if none of the three experienced IRRs of grade
C3, the 90-min infusion was then tested for the
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remaining patients. Overall, 51 of 80 patients
(64%) experienced IRRs, most of which were of
grade 1–2 in severity and reported in cycle 1.
There were no IRRs of grade C3 with the 90-min
infusion [85].
GATS Study (JapicCTI-152848)
SDI with obinutuzumab in combination with
chemotherapy (CHOP) is also being
investigated in a phase II study in Japanese
patients (Table 2) receiving first-line therapy for
various types of CD20-positive B-cell NHL.
In cycle 1, all patients receive obinutuzumab
1000 mg on day 1 over 4.25 h and on days 8 and
15 over 3.25 h. Patients who meet the criteria
for SDI (no serious and/or grade C3 IRRs in the
first three infusions and lymphocyte count
B5000/ll prior to SDI) receive their next
obinutuzumab infusion over 1.5 h. The
primary objectives of the study are to evaluate
infusion tolerability, pharmacokinetics, and
change in cytokine levels over time.
FUTURE PERSPECTIVES
Since the introduction of rituximab in 1997, great
advances have been made in the management of
lymphoma and lymphocytic leukemia of B-cell
origin. The formulation of truly novel treatment
paradigms has been made possible, and multiple
avenuesof researcharenow being exploredtofind
new and more effective ways of applying targeted
therapy to maximize tumor responses and OS,
while minimizing AEs and patient discomfort.
This includes the expansion of combination
therapy choices to include multiple targeted
agents with the potential for reducing reliance
on chemotherapy. Chemotherapy-free
combinations have the potential to further
optimize effector functions, and anti-CD20
therapy can reasonably be considered as a base
treatment option. Anti-CD20 therapy holds great
promise for the future management of B-cell NHL,
and several novel entities are under development.
Several trials are now evaluating
obinutuzumab in combination with other
targeted therapies in B-cell NHL. The phase Ib/
II GALEN study (NCT01582776) is evaluating
obinutuzumab in combination with
lenalidomide in relapsed/refractory and
first-line FL patients and in patients with
aggressive B-cell lymphomas (DLBCL and
MCL). Phase Ib data from this study have
already shown that the combination is
effective, with an objective response in 13 of
19 evaluable patients, including 7 CRs [107].
Other similar studies include the GO27834
(ROMULUS) study (NCT01691898), a phase II
study in which combinations of obinutuzumab
or rituximab with the anti-CD79b
antibody–drug conjugate, polatuzumab
vedotin, are being tested in patients with
relapsed/refractory B-cell NHL. In addition, the
phase II GO29365 study (NCT02257567) is
evaluating polatuzumab vedotin in
combination with rituximab or obinutuzumab
and bendamustine in patients with relapsed/
refractory FL or DLBCL. The novel oral BCL-2
inhibitor, GDC-0199 (ABT-199; venetoclax), is
being investigated in a phase I/II study
(GO27878; NCT02055820) in combination
with rituximab or obinutuzumab plus CHOP
in patients with B-cell NHL, while the phase I
GO29383 study (NCT02220842) is assessing
obinutuzumab in combination with
atezolizumab (MPDL3280A) in relapsed/
refractory FL and DLBCL. Atezolizumab is a
fully humanized antibody that acts against the
protein ligand PD-L1.
There are also two phase III studies ongoing
in first-line CLL. The CLL14 study
(NCT02242942) will compare the efficacy and
safety of a combined regimen of obinutuzumab
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and venetoclax versus obinutuzumab plus
chlorambucil in patients with CLL and
coexisting medical conditions. The anticipated
time on study treatment is approximately
1 year, with a follow-up period of up to
5 years. The second study is evaluating the
combination of obinutuzumab and ibrutinib, a
Bruton’s tyrosine kinase inhibitor, compared
with obinutuzumab plus chlorambucil in
patients with CLL or small lymphocytic
leukemia (NCT02264574). Follow-up is
planned for up to 3 years.
Other open-label, multicenter phase Ib/II
studies in which obinutuzumab is being used
in combination with other investigational
agents include atezolizumab plus
obinutuzumab and CHOP or bendamustine in
first-line FL and DLBCL (NCT02596971);
atezolizumab plus obinutuzumab and
lenalidomide in relapsed/refractory FL
(NCT02631577); atezolizumab plus
obinutuzumab and polatuzumab vedotin in
relapsed/refractory FL and DLBCL
(NCT02729896); obinutuzumab plus
polatuzumab vedotin and lenalidomide in
relapsed/refractory FL and DLBCL
(NCT02600897); obinutuzumab plus
polatuzumab vedotin and venetoclax in
relapsed/refractory FL and DLBCL
(NCT02611323); and obinutuzumab plus
idasanutlin (an MDM2 antagonist) in relapsed/
refractory FL and DLBCL (NCT02624986). A
phase Ib study examining the combination of
obinutuzumab plus idasanutlin and venetoclax
is also planned.
A large number of other molecular targets are
being explored for their therapeutic potential in
hematologic malignancies; these are beyond
the scope of this review and are discussed
elsewhere [45]. However, novel approaches
designed to promote targeting of tumors by
T-cells are also being investigated. Bispecific
T-cell engagers (BiTE) contain the variable
domains of two antibodies joined together,
one of which binds CD19, while the other
binds T-cell CD3 [108]. The creation of a CD19/
CD3 complex brings tumor and T-cells together
in close proximity, which in turn activates the
T-cell and causes it to destroy the tumor cell via
perforin-mediated apoptosis [45]. Other
researchers are exploring the potential of
anti-CD20/CD3 bispecific antibodies to
overcome problems of short half-life in vivo,
structural instability, and poor solubility of
anti-CD19 BiTEs [109–111]. Another approach
is modification with chimeric antigen receptors
(CARs) of T-cells to confer tumor-specific
cytotoxicity [112]. Preclinical and clinical
studies of CD19 CAR-T-cells have shown
encouraging results in a variety of cancers,
particularly B-cell hematologic malignancies
[113].
There is also a need to explore the potential
applicability of surrogate endpoints in
hematologic malignancies to help direct
therapy and to expedite the conduct of
clinical trials. Positron emission tomography
using 18-fluoro-2-deoxyglucose has become a
standard clinical tool for staging and response
assessment in aggressive lymphomas, and
results from a number of studies indicate its
potential utility in predicting outcomes in
patients with DLBCL and FL [114, 115].
Another approach is to measure MRD (as
described above for GADOLIN and CLL11)
[88, 96], which can be used for evaluation of
treatment effectiveness, risk stratification, and
long-term outcome prediction. While
multicolor flow cytometry and polymerase
chain reaction-based methods are currently
the two most commonly used techniques for
assessing MRD, next-generation sequencing is
likely to be more widely employed in the future
[116].
Adv Ther (2017) 34:324–356 349
PFS is the standard endpoint for assessing
new drugs in first-line FL, but the increasing
efficacy of new treatments and the indolent
nature of FL demand extended patient
follow-up in clinical trials [117]. There is
therefore interest in whether CR at 30 months
(CR30) could accurately predict likely treatment
effects on PFS. A recent meta-analysis of data
from 13 randomized, first-line trials in 3837
patients with individual patient data has
supported this hypothesis [117]: an absolute
improvement in CR30 of C10% over a control
CR30 of 50% predicted a significant
improvement in PFS. This suggests that CR30
has utility as a surrogate for PFS in first-line FL
trials and supports its use to facilitate treatment
development.
In conclusion, researchers are continuing
their efforts to develop increasingly efficient
therapies that provide long treatment-free
periods for patients with relapsing or
refractory disease, to identify the most
effective combination therapies (notably
triplet combinations) and, as discussed above,
to develop chemotherapy-free regimens based
on immunotherapy. The advances with
obinutuzumab described here against the
background of the many other therapeutic
approaches that are underway are evidence of
marked and significant progress in the
development and application of
immunotherapy against lymphocytic leukemia
and B-cell lymphoma.
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